Volume 11 — April 10, 2014
Comparison of Fecal Occult Blood Tests for Colorectal Cancer Screening in an Alaska Native Population With High Prevalence of Helicobacter pylori Infection, 2008–2012
Among 2,340 participants scheduled for colonoscopy, 1,640 were excluded for the following reasons: no endoscopy or endoscopy was scheduled for the next day, 570; not living in Anchorage, 369; not Alaska Native, 203; not able to stop medications, 166; colorectal cancer symptoms, 98; comprehension, 87; and other, 147. Of the 700 who were eligible for the study, 303 declined to participate. Among the 397 who were enrolled in the study, 93 were excluded for the following reasons: iFOBT/gFOBT incomplete, 29; colonoscopy incomplete, 19; H. pylori test incomplete, 3; and other, 42. This left 304 who completed the study.
Figure. Flow diagram for enrollment in a study of fecal occult blood tests among Alaska Natives, Anchorage, Alaska, 2008–2012. Abbreviations: CRC, colorectal cancer; iFOBT, immunochemical fecal occult blood test; gFOBT, guaiac-based fecal occult blood test; H. pylori, Helicobacter plyori.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions.